

Livingston Securities

6th annual “Life Science Stakeholders Summit”

Thursday, October 17th

9am – 5pm

**Location – Offices of sponsor Akerman Senterfitt
666 Fifth Ave (between 52nd and 53rd Streets)**

Agenda

845 registration & coffee

915 Welcome - Ernie Stern, Partner – Akerman Senterfitt

930am welcome - Mostafa Analoui

10am Keynote - Brock Reeve - Harvard Stem Cell Institute

1030am - Roundtable 1 - Corporate deal making - (names TBD)

1130am - Roundtable 2 – Startups from America’s Leading Innovation Clusters and Centers of Excellence

1230 - Lunch keynote - Aubrey de Grey - SENS Foundation

1pm - Roundtable 3 – Biotech IPO Frenzy – Boom or Bubble –

2pm - Roundtable 4 – Personalized Medicine – Smart Therapeutics, Diagnostics & Combination Therapies

3pm - Keynote - Scott Livingston, CEO of Livingston Securities – The JOBS Act, the Return of the Small IPO, and Changes in the Way that Innovation is Financed on Wall Street

4pm - Roundtable 5 – The Future of Healthcare, 2014 and Beyond

5pm – Closing Comments – Mostafa Analoui

515pm – Drinks and Networking

Livingston Securities

6th annual “Life Sciences Stakeholders Summit”

Individual Company Presentation Schedule

Pitchroom (A & B)

1030am - Northwest Biotherapeutics (A)

1050am - ADHD My Way (A)

1110am - Zero Gravity Communications (A)

1130am - Quotient Pharma (A)

1150am – Hepregen (A)

1210am - BioSculpture Technologies (A)

130pm - Phoenix Pharmalabs (A)

150pm - Amaranthus (A)

210pm - Neostem (A) & Simbiot (B)

230pm - NanoBiosym (A)

250pm - Boston TI (A)

310pm - TEK Capital (A)

330pm - Provista Diagnostics (A)

350pm - Neurotez (A) & PDS Biotech (B)

410pm – Allovate Inc. (A)

Livingston Securities

6th annual “Life Sciences Stakeholders Summit”

Speaker Bios

UMESH AMIN - EXECUTIVE VICE PRESIDENT, TEK CAPITAL

Umesh has over 20 years of global wireless industry executive leadership experience in creating share-owner value by launching and transforming businesses. He has led multi-functional business, technology, and legal teams to monetize intellectual property in the global market place. Umesh was president of the wireless/communications business unit at Intellectual Ventures (IV), an invention capitalist entity with over \$5B under management. At IV Umesh built a world class licensing team and launched multiple licensing programs that resulted in over \$300M in licensing revenue.

Previously, Umesh was President & COO of Telsima Inc. Where he transformed the existing wireless-messaging business to a leading provider of VoIP-systems through M&A. Umesh served as Senior Director of the New Technologies and Services Planning at AT&T Wireless Services (AWS). At AWS he built the company patent portfolio from less than ten assets to over 400 assets and launched their monetization effort.

Umesh has been awarded over 30 patents and holds an undergraduate and graduate degree in Electrical Engineering from the City College of New York. He has also completed a mini-MBA from the Wharton School of Business.

MOSTAFA ANALOUI - HEAD OF HEALTHCARE, LIVINGSTON SECURITIES

Mostafa Analoui, Ph.D., is Head of Healthcare and Life Sciences at The Livingston Group (New York, NY) and Chairman and CEO of Cense Biosciences, Inc. Previously he was the Senior Director at Pfizer Global Research and Development. He is also adjunct Professor of Oral Pathology, Medicine and Radiology at Indiana University. Dr. Analoui is actively involved in investment, management and scientific/business development of nanotechnology, drug discovery/development, diagnostic imaging, and global strategies. While at Pfizer, he was the Site Head for Global Clinical Technology in Groton and New London, a division focusing on emerging technologies for development and validation of biomarkers and diagnostics for drug development. Prior to joining Pfizer, Dr. Analoui was the Director of Oral and Maxillofacial Imaging Research, Associate Professor of Radiology at Indiana University, and Associate Professor of Biomedical Engineering and Electrical & Comp Engineering at Purdue University. He was also President and CEO of Therametric Technology Inc. He has received his Ph.D. from Purdue University, followed by Post-Doctoral Fellowship at IBM TJ Watson Research Center in NY.

In addition to industry leadership in biomedical and technology fields, he consults and lectures in US, Europe and Asia. He has also served on various scientific, regulatory, and business advisory committees and boards, including NIH, NSF, PhRMA, NASA, and

OECD. Dr. Analoui has authored over 130 publications, including journal articles, book chapters, and technical reports. He is senior member of IEEE, SPIE, and RSNA. He currently serves as board member of VirtualScopics (Nasdaq: VSCP), Calando Pharmaceutical (Nasdaq: ARWR), BEACON (Biomedical Engineering Alliance and Consortium) and NanoBusiness Alliance. Dr. Analoui's registrations include Series 7 and 63 with Livingston Securities LLC, a subsidiary of The Livingston Group.

MICHAEL BAKER - FOUNDER and PARTNER - BAKER GROUP LLP

Mr. Baker has 27 years of executive management experience, including merger and acquisitions with Philips Medical, Lockheed Martin and GE. He has launched multiple entrepreneurial ventures in the medical device, medical IT and clean tech industries. Among these, most notable are the original picture archiving and communications system (PACS), an award-winning through wave acoustic holography system for non-radiation breast imaging and an ultra high-efficiency electric motor for use in alternative energy applications. In addition to being the Managing Partner at Baker Group LLP, Mr. Baker is President and CEO of Otoharmonics Corp, CEO of Applied Exergy, Ltd. and Chairman of the Board for Oregon BEST.

FRANK BEDU-ADDO - PRESIDENT & CEO, PDS BIOTECH

Dr. Bedu-Addo is a veteran executive and bio-entrepreneur with experience successfully starting and growing biotechnology organizations. He has been responsible for the development and implementation of both operational and drug development strategies, supervising and managing both large organizations as well as emerging biotechnology companies. Dr. Bedu-Addo was a founding and senior executive member of KBI BioPharma, Inc. As Vice President of Drug Development he oversaw all business and drug development operations. Before being hired by KBI, he successfully started and managed Cardinal Health's east coast biotechnology drug development operations. Prior to Cardinal Health, Dr. Bedu-Addo was also an Associate Director at Akzo-Nobel, Senior Scientist at Elan (The Liposome Co.), and Principal Scientist at Schering-Plough. In these positions he participated in the development of numerous drugs, including antiviral and anticancer drugs. He serves on the board of directors of BioConvergence, LLC, an early stage biotechnology company. Dr. Bedu-Addo obtained his M.S. in chemical engineering and Ph.D. in pharmaceuticals from the University of Pittsburgh.

ERICK BERGLUND – CHIEF EXECUTIVE OFFICER – ALLOVATE INC

Dr. Berglund received his BS and MS from the University of N.H. and Boston University School of Medicine, respectively, then received his PhD in biochemistry from Goethe University in Frankfurt, Germany.

He initially worked as a researcher at Sanofi - Aventis, then became a USPTO registered patent agent, going on to work in business development and strategy at Kyorin Pharmaceuticals, and then as CEO of Vaxiva KK, a Tokyo-based vaccine company.

Prior to launching Allovate, Dr. Berglund was a Medical Strategy Director at H4B Chelsea, a global healthcare communications consultancy in NYC.

MICHAEL BUI - RUTGERS UNIVERSITY SCHOOL OF PUBLIC HEALTH

Adjunct Assistant Professor; Associate Director, Global Regulatory Affairs, Bayer Healthcare Pharmaceuticals, Inc. DDS, 1999, Columbia University, College of Dental Medicine; MPH, 1999, Columbia University, School of Public Health; JD, 2003, State University of New York at Buffalo, School of Law. Research Interests: Pharmacovigilance and Regulatory Affairs

GERALD COMMISSIONG - PRESIDENT & CEO, AMARANTUS BIOSCIENCES

Mr. Commissiong is President & CEO, BioScience and a member of the Board of Directors of Amarantus, the company he co-founded with John Commissiong, PhD in 2008. From the inception of the Company, Mr. Commissiong attracted seed capital, acquired the intellectual property rights to MANF and recruited scientific and executive talent to Amarantus to allow for the further development of the technologies. Prior to becoming CEO in October 2011, Mr. Commissiong was the Chief Operating Officer where his duties included strategic transactions, licensing, research collaborations, mergers and acquisitions, and fund raising. From August 2009 until March 2011, he served as Chief Business Officer where he was responsible for business and corporate development. Prior to co-founding Amarantus, Mr. Commissiong played professional football for the Calgary Stampeders of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering with a focus on Financial Decisions from Stanford University

WILLIAM CROSSMAN - PRESIDENT, PHOENIX PHARMALABS INC.

William Crossman is a senior management professional with international and domestic experience as CEO, COO and CFO of enterprises ranging from entrepreneurial start-ups to Fortune 100 level companies. He has a proven track record of successfully commercializing emerging technologies.

Mr. Crossman has assisted numerous early-stage companies to refine business strategies, commercialize new products, raise capital, license technologies, scale revenues and production, and expand into global markets. These companies include Embedded Nanomagnetism, Inc. and Inframat Corp. (nanotechnology), Intelpresence, Inc. (defense systems), Ensolve, Inc. (marine bioremediation products), Quantum Dynamics, Inc. (clean energy technology), Frozen Process Technologies, Inc. (specialized manufacturing systems), and Blackbird Trading LP (quantitative investment trading systems).

As CEO of ISOPur Fluid Technologies, Crossman led the company from product introduction to global growth with expanding applications in multiple vertical markets. Important strategic alliances were developed with Siemens, BHP, Atlas Copco, Hess, Sanwa Shoko and others, creating a platform for continued strong growth. The value of

the founding shareholders' common stock increased more than tenfold in less than three years under Crossman's leadership.

ROBERT CUCIN - PRESIDENT - BIOSCULPTURE TECHNOLOGY

Robert L. Cucin, M.D., F.A.C.S . is a practicing plastic surgeon in Manhattan affiliated with The Presbyterian - New York, Beth Israel North and New York University Downtown Hospitals. He received his undergraduate training from Cornell University where he received his B.A. and graduated magna cum laude in chemistry and with distinction in all subjects.

Dr. Cucin set up the prestigious American Institute of Plastic Surgery in a landmark Beaux Arts mansion in Manhattan where pampered patients underwent plastic surgery in the state of the art ambulatory surgical facility which received the highest rating from the American Association for Accreditation of Ambulatory Plastic Surgical Facilities. After staying over in private rooms with working fireplaces, having been tended by a live-in private nurse with a doctor on call at all times, the patients were ushered by the uniformed doormen into a chauffeur-driven Rolls Royce for their trip to the airport or home. The staff enjoyed their cameos in the weekly informational series, Keeping Face and Figure, which aired for five years on three cable networks serving the tri-state area. It featured patients who underwent computer imaging before their planned surgeries, discussions of the operations with occasional footage, and the postoperative patients return to the show with comments about their experience.

AUBREY DE GREY - CO-FOUNDER & CHIEF SCIENCE OFFICER - SENS FOUNDATION

Dr. de Grey is the biomedical gerontologist who researched the idea for and founded SENS Research Foundation. He received his BA in Computer Science and Ph.D. in Biology from the University of Cambridge in 1985 and 2000, respectively. Dr. de Grey is Editor-in-Chief of Rejuvenation Research, is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations

BRENDA EDIN – MANAGING DIRECTOR – BAKER GROUP

With 16 years experience in business development, Ms. Edin has proven performance in the development and implementation of integrated commercialization, marketing and business growth strategies. Through her role as Partner at the Baker Group LLP, she has been a critical participant in advancing multiple emerging technology companies, including Home Dialysis Plus, Otoharmonics Corp and Apex Drive Laboratories. With expertise in human factors and usability, Ms. Edin is focused on leveraging technologies that enhance clinical outcomes through patient engagement. In addition to being a Partner at Baker Group LLP, Ms. Edin is Chief Marketing Officer at Otoharmonics and Portland State University Venture Fund committee member.

ANITA GOEL - CHAIRMAN & CEO, NANOBIOSYM

As Chairman and CEO of Nanobiosym® and Nanobiosym® Diagnostics, Dr. Goel is focused on delivering new game-changing technologies to address the greatest unmet needs in global health, energy, and the environment.

A Harvard-MIT-trained Physicist-Physician, Dr. Anita Goel is a globally recognized leader in the emerging field of nanobiophysics—a new science at the convergence of physics, nanotechnology, and biomedicine. Nanobiophysics integrates these three fields to reveal new scientific solutions to the world's most pressing challenges.

Her pioneering contributions to nanotechnology and nanobiophysics have been recognized globally by prestigious honors and awards including multiple awards from US Government agencies such as Defense Advanced Research Projects Agency (DARPA), Department of Defense (DOD), Department of Energy (DOE), Air Force Office of Scientific Research (AFOSR) and US Defense Threat Reduction Agency (DTRA). She established Nanobiosym® Diagnostics to commercialize the Gene-RADAR® technology platform to empower people worldwide with portable, rapid and accurate information about their own health. Employing the latest advances in nanotechnology, Gene-RADAR® is a fully portable, chip-based diagnostic that can recognize any disease with a genetic fingerprint from a single drop of blood or saliva without the need for lab infrastructure, trained health care personnel, electricity or running water

JIM GUNTON - GENERAL PARTNER - NJTC VENTURE FUND

Jim has been investing in privately-held growth technology companies for more than 18 years. Before co-founding in 2001 the \$80 million NJTC Venture Fund, Jim was a Vice President at Edison Venture Fund and a manager at Oracle Corporation in the Silicon Valley. He represents NJTC Venture Fund at six portfolio companies and is a former Governor of the National Association of Small Business Investment Companies. Jim earned a BS from Stanford University and an MBA with distinction from Duke University.

KIMBERLY HA - GLOBAL EDITOR - BIOPHARM INSIGHT

Kimberly is an award-winning biopharmaceutical industry journalist and editor. She launched BioPharm Insight's editorial team in 2007. She began her career as a financial journalist in Hong Kong specializing in healthcare M&A, and previously was the lead sector specialist at Mergermarket, a division of the Financial Times Group.

She is a sought-after panelist and moderator at major healthcare investor conferences and events, including the Prix Galien Awards. In 2011, based on her extensive coverage of Alzheimer's disease, she was nominated by the Alzheimer's Association and was ultimately selected to be a National Press Foundation Fellow. Kimberly also is a recipient of the 2012 National Press Foundation and UN Foundation Global Vaccines Press Fellowship. In 2012, she was awarded the Association of Health Care Journalists

Fellowship Award, which was supported by the New York State Health Foundation as well as the National Press Foundation Cancer Issues Fellowship.

Kimberly completed her Bachelor's in Psychology from New York University. She is fluent in Cantonese, Shanghainese, and is proficient in Mandarin.

**LYNT JOHNSON - ROBERT J. COFFEY PROFESSOR and CHAIR,
DEPARTMENT OF SURGERY - GEORGETOWN UNIVERSITY HOSPITAL**

Specialties

Primary Specialty: Pancreatic Surgery Secondary Specialty: Liver and Bile Duct Surgery Tertiary Specialty: Minimally Invasive Surgery Quaternary Specialty: Transplant Surgery

Special Interests

Liver masses and tumors, including minimally invasive liver resection, Pancreas cancer and tumors, including minimally invasive pancreas resection, Bile duct resection and repair, Liver transplant, Hepatobiliary surgery, Liver ablative therapies, Kidney transplant, Radiofrequency ablation

Education

Medical School: Harvard Medical School, 1985 Internship: Massachusetts General Hospital, 1985 Residency: Massachusetts General Hospital, 1991 Fellowship: New England Deaconess Hospital, Transplant and Hepatobiliary Surgery, 1993 Certification(s): General Surgery, 1992

MARTIN JOYCE - CHIEF FINANCIAL OFFICER - HEPREGEN

Mr. Joyce's professional background includes C-level leadership roles in public and private, medical device, biotechnology and pharmaceutical companies from start-up stage to \$500 million in annual revenue. Mr. Joyce has extensive experience in public equity financings, business development, SEC reporting, strategic planning, mergers, acquisitions, investor relations and biotechnology operations. Previously, Mr. Joyce was chief financial officer at Lucid Inc., an early stage skin cancer diagnostic company. Prior to Lucid, Mr. Joyce was executive vice president and chief financial officer at BioSphere Medical, Inc., a publicly traded company that sold embolic products and a drug delivery platform for the treatment of liver cancer. BioSphere was acquired by Merit Medical in September of 2010. Earlier in his career Mr. Joyce held a variety of senior-level positions in finance, sales, marketing and manufacturing at the biotechnology company Serono, Inc., ultimately serving as chief financial officer for North America. Mr. Joyce holds a B.S. in finance from Northeastern University, and an M.B.A. from Suffolk University.

HARVEY KAYE - CHAIRMAN, ZERO GRAVITY SOLUTIONS

Mr. Kaye has more than 30 years of experience in providing financing, strategic planning and administrative leadership to large and small companies, both public and private, as an

entrepreneur, investment banker, chairman, chief executive officer and director. Mr. Kaye was formerly founder, chairman, chief executive officer and president of Latitude Solutions, Inc. Latitude Solutions, Inc., is a publicly traded holding company for several subsidiaries which provide products, processes and services for contaminated water applications. He was previously Chief Executive Officer and President of Gulfstream Capital, L.C., a merchant banking, consulting and financial advisory organization which provides advisory and corporate finance services to both public and private companies. Gulfstream has acted in a merchant banking, financial advisory and strategic planning capacity for numerous corporations, both public and private. Mr. Kaye has a BS in business from Temple University

MICHAEL LOFTUS – DIRECTOR OF BUSINESS DEVELOPMENT - INTEGRIUM CORP

ANTHONY MAIDA - CHIEF OPERATING OFFICER, NORTHWEST BIOTHERAPEUTICS

Anthony E. Maida joined Northwest Biotherapeutics in June, 2011, as Chief Operating Officer bringing more than 20 years' experience in building oncology companies, with expertise in the business, financial, clinical and regulatory aspects of and the underlying science of oncology business. Over these two decades, Dr. Maida has held positions as Chairman, CEO, COO, CSO, CFO and VP Business Development. Among these experiences, he served as CEO of CancerVax Corporation, an early leader in cancer vaccines. In that role, he was responsible for conducting multi-hundred patient, multi-center clinical trials with the company's cancer vaccines. Prior to joining us, Dr. Maida was serving as global head of oncology for a leading contract research organization that manages clinical trials in the U.S. and internationally.

CHIP PIEPER – CHIEF EXECUTIVE OFFICER – ADHD MY WAY

Chip has spent more than 20 years working in the enterprise software and cleantech industries. His experiences range from managing multi-million dollar technology centers for Microsoft Corporation, co-founding venture-backed software start-ups such as SCIenergy and info-one, managing large software sales and technology teams for K2, overseeing global ERP and business process automation deployments, managing international channel programs, authoring many industry articles, to teaching 8th grade social studies and instructing technology courses at Marquette University.

ELEMER PIROS - BURRILL & CO

Elemer Piros is a Managing Director of Research for Burrill & Co. Mr. Piros joined Burrill & Co. from Rodman & Renshaw, where he served as a managing director and senior biotechnology analyst since 2002. He has ranked among the top analysts in various surveys, including ranking as the top biotechnology analyst by the Wall Street Journal in 2006 and by the Financial Times in 2010, based on stock portfolio performance. Prior to that, he served as a senior biotechnology analyst at Ladenburg Thalmann, and as a

biotechnology research analyst with Spear, Leeds & Kellogg/Goldman Sachs. Before serving as an analyst, Piros spent eight years conducting research in biophysics, biochemistry and molecular biology at Cornell University and the University of California, Los Angeles. He holds a doctorate in neurosciences from UCLA, a bachelor's degree in biology from UCLA, and a bachelor's degree in mathematics and technology from Eotvos Lorand University in Budapest.

DAVID PLATT - CHAIRMAN & CEO, BOSTON THERAPEUTICS

Dr. Platt is a world-renown expert in carbohydrate chemistry and has founded three publicly-traded companies, creating nearly \$1B for investors. He has lead two drug candidates from concept to human clinical trials. Prior to Boston Therapeutics, from 2001 to 2009, Dr. Platt was a Founder, Chief Executive Officer and Chairman of the Board at Pro-Pharmaceuticals, Inc., SafeScience, Inc. and International Gene Group, all publicly-traded companies

DAVID POLLACK - CHIEF EXECUTIVE OFFICER, QUOTIENT PHARMA

David Pollack is a financier with far-reaching experience spanning a wide range of business activities, including commercializing new technology, underwriting and capital funding. With a strong background in corporate, secured-debt and project finance, David has raised significant capital across multiple business sectors and has represented more than 100 financial institutions, including some of the nation's largest.

In 1998, Pollack saw the commercial potential of an innovative nanotechnology-based steel product and co-founded MMFX Technologies Corporation. At MMFX, he played an integral role in securing more than \$120 million of capital for the company. This resulted in the commercialization of "game-changing" steel products and the initial capitalization of a 450,000 ton annual capacity specialty steel mill. As co-inventor of many of MMFX's key patents, he was instrumental in expanding and securing MMFX's technology through the filing of seven US patents and more than 200 foreign applications.

As the son of prominent immunologist Dr. William Pollack, David has long been under the tutelage of his esteemed father. In late 2004, David founded Quotient and promptly identified and procured specific plasma donors. In 2006 he designed and built the company's clean rooms and laboratories. Capitalizing on Dr. Pollack's immense knowledge, David has worked side-by-side with his father to capture and document a precise fractionation-manufacturing process and then produced the Streptococcus Pneumoniae human antibody solution that is the basis of Quotient Pharmaceuticals' efforts.

DAVID REESE - CHIEF EXECUTIVE OFFICER - PROVISTA DIAGNOSTICS

Dr. Reese, Ph.D. was appointed President and CEO of Provista in 2011. Prior to joining Provista, Dr. Reese was a Managing Director at Brencourt Advisors, LLC where he was

responsible for managing healthcare investments for across their funds from 2008 to 2011. From 2005 to 2007, he was a managing director at Yorkville Advisors, establishing their healthcare group which engaged in active early funding of biotechnology, medical device and diagnostic companies. Dr. Reese's success in finance has been spurred by his Ph.D. in biomedical sciences from Vanderbilt, and is the author of numerous peer-reviewed publications, presentations, book chapters, and reviews. He completed his postdoctoral training as a National Institutes of Health as a sponsored research associate.

BROCK REEVE - EXECUTIVE DIRECTOR - HARVARD STEM CELL INSTITUTE

Brock Reeve is Executive Director of the Harvard Stem Cell Institute. In partnership with the Faculty Directors, he has overall responsibility for the operations and strategy of the Institute whose mission is to use stem cells, both as tools and as therapies, to understand and treat the root causes of leading degenerative diseases.

HSCI is comprised of the schools of Harvard University and all its affiliated hospitals and research institutions. Under the leadership of the Executive Committee, HSCI invests in scientific research in three main areas – seed grants, core facilities and large-scale disease programs. HSCI's faculty membership has grown to almost 300 Principal and Affiliated Faculty. The Institute is now engaged with several leading pharmaceutical companies in joint research projects and its faculty have founded several stem cell-related startup companies and serve on leading Scientific Advisory Boards.

Brock came to this role from the commercial sector with extensive experience in both management consulting and operations for technology-based companies, with a focus on life sciences. His clients have included some of the leading pharmaceutical, biotechnology and medical device companies, and he also has had hands-on operational responsibility in product management and marketing roles in software start-ups. Brock received a BA and MPhil from Yale University and an MBA from Harvard Business School.

ALLEN ROSES - PROFESSOR OF MEDICINE, DUKE UNIVERSITY and FOUNDER, ZINFANDEL PHARMACEUTICALS

Allen D. Roses has established an international reputation for his work in pharmacogenetics, exploratory drug discovery, and clinical neuroscience.

Dr. Roses founded Cabernet Pharmaceuticals in 2008 to provide pharmacogenetics (PGx) and project-management services to pharmaceutical and biotechnology companies, clinical-research and managed-healthcare organizations, and academic institutions. He has formed a team of consultants with deep experience in the practical application of PGx to drug development.

Dr. Roses also serves in several capacities at Duke University: as Jefferson-Pilot Professor of Neurobiology, and Genetics, as Professor of Medicine (Neurology) as Director of the Deane Drug Discovery Institute, and as Senior Scholar at the Fuqua School of Business.

He recently returned to Duke after a decade-long career as a Senior Vice President at GlaxoSmithKline (GSK) and its corporate predecessor GlaxoWellcome (GW). Upon joining GW in 1997, he organized genetic strategies for susceptibility-gene discovery, pharmacogenetics strategy and implementation, and integration of genetics into medicine discovery and development. Subsequently at GSK, he headed research in genetics, genomics, proteomics, and bioinformatics in support of the entire R&D pipeline.

ROBIN SMITH - CHIEF EXECUTIVE OFFICER, NEOSTEM INC.

Dr. Smith's expertise in business development and medicine includes her extensive and diversified experience serving in executive and board level capacities for various medical enterprises and healthcare-based entities. Since 2006, she has served as chairman and CEO of NeoStem, a rapidly growing company in the stem cell sector. In 2010, NeoStem earned the New Economy "Best Stem Cell Company" award and, in 2012, was named the fastest-growing technology, media, telecommunication, life sciences and clean technology company in the Tri-State New York area and number seven in North America by the Deloitte Technology Fast 500™. While at NeoStem, she has successfully completed five acquisitions and one divestiture as well as raised over 100 million dollars toward building one of the leading companies in the emerging cell therapy industry. Dr. Smith has acted as a senior advisor to, and investor in, companies where she has played a significant role in restructuring and/or growth. She currently serves on the board of trustees of the NYU Langone Medical Center and is past chairman of the board for the New York University Hospital for Joint Diseases where she headed up new development efforts and board member recruitment. Currently, Dr. Smith is the president and chairman of the board of The Stem for Life Foundation. She was also appointed to the board of directors, Science and Faith STOQ Foundation in Rome and the Capital Formation Committee of the Alliance for Regenerative Medicine.

Dr. Smith received her M.D. degree from Yale University and was presented with the Janet M. Glasgow Memorial Achievement Citation awarded by the American Medical Women's Association to women who graduate first in their class from medical school. She was also elected to Alpha Omega Alpha and chosen to be a Farr Scholar. She received her M.B.A. degree from the Wharton School of Business in the top 10% of her class.

ERNEST STERN - PARTNER - AKERMAN SENTERFITT

Ernest Stern's Corporate and Securities practice includes the representation of public and private emerging companies, many of which are technology based. Ernest assists these clients in their growth plan through venture financing in the form of private placements with high net worth individuals, institutional venture capital, PIPE investments, and IPOs. Recently, Ernest handled one of the first 20 confidential IPO filings under the

JOBS Act for an emerging growth company. Additionally, he advises companies in cross-border and domestic mergers and acquisitions, and he has extensive experience in advising on SEC and NASD compliance issues.

MARTIN TOLAR - CHIEF EXECUTIVE OFFICER, ALZHEON INC.

Dr. Martin Tolar, MD, PhD, serves as the Chief Executive Officer and President of Alzheon, Inc. Dr. Tolar served as the Chief Executive Officer of Knome, Inc. since January 9, 2012 and also served as its President. Dr. Tolar has over 10 years of experience working in the biopharmaceutical industry. Dr. Tolar served as the President and Chief Executive Officer at NormOxys, Inc. since December 4, 2009, where he established the foundation for the business--including building a professional management team, securing venture financings, and successfully advancing its novel cancer therapeutics from a research project into clinical development. Dr. Tolar joined NormOxys from CoMentis, Inc., where he served as Chief Business Officer since April 2008 and also served as its Executive Vice President. Dr. Tolar served as Chief Scientific Officer of CoMentis, Inc. and also served as its Vice President of Strategic and Corporate Development since June 6, 2007 and he led the development organization and negotiated a \$760 MM beta secretase collaboration agreement with Astellas Pharma. Dr. Tolar served at Pfizer for six years in a variety of leadership positions in Clinical Development and Alliance Management & Business Development. Dr. Tolar served as Consultant for Apologic, Inc. and Genzyme Corporation. He served as Director of Neuroscience Worldwide Business Development at Pfizer Global Pharmaceuticals, where Dr. Tolar was responsible for licensing and outreach activities in Neurology and Psychiatry, including the recent acquisition of Rinat Neurosciences and the license of the RAGE platform from TransTech Pharma. Prior to Neuroscience Licensing, Dr. Tolar served as the U.S. Clinical Leader for indiplon, an insomnia treatment developed with Neurocrine Biosciences, where he was responsible for the conduct of clinical trials and the New Drug Application (NDA) filings for immediate and modified release formulations. Dr. Tolar served as Chairman of Neuroscience Licensing Team at Pfizer. Dr. Tolar served in several senior positions in pharmaceutical and biotechnology companies. He has been a Director of BELLUS Health Inc. since October 2010. He serves as a Director of Asian Clinical Trials Private Limited and of Alzheon, Inc. He served as Director of and Knome, Inc. Dr. Tolar was an Assistant Professor in the Department of Neurology at Yale University School of Medicine. He has published more than 20 scientific papers and posters in the area of Neurosciences. He served as an Independent Non-Executive Director of Suven Life Sciences Ltd. from July 2009 to January 16, 2013. He received his M.D. from the 2nd Medical School, Charles University in Prague, Czech Republic, and his Ph.D. in Neuroscience from the University of Cincinnati in Ohio for his work on the role of apolipoprotein E in Alzheimer's disease. Dr. Tolar completed an Internship in Internal Medicine at the Christ Hospital in Cincinnati and a Residency in Neurology at the Boston Medical Center.